Dyne Therapeutics Targets 2026 “Breakout Year” With DMD BLA Plans and DM1 Milestones at ...

Dyne Therapeutics (NASDAQ:DYN) executives outlined a slate of 2026 operational and regulatory milestones during a discussion with Stifel, emphasizing plans to transition toward a commercial-stage ...

Salesforce: AI Is Not The Problem, Architecture Is

While Salesforce has mitigated SaaSpocalypse risks via Anthropic, its Frankenstein architecture creates a heavy Integration ...